CYCN News and Press, Cyclerion Therapeutics Inc. From 10/06/22

Cyclerion Therapeutics ( NASDAQ: CYCN ) on Thursday said it would reduce its workforce by about 45% as part of a strategic prioritization to focus its resources on the development of its therapy CY6463 for the treatment of mitochondrial diseases. Shares of the micro-ca...

Recent positive MELAS clinical study data drive urgency to deliver potential first-ever therapy for patients with rare, genetic mitochondrial diseases Development programs prioritized and organization structured to align with mitochondrial disease-focused strategy ...

Study data demonstrate positive effects of CY6463 on cognition and inflammation after two weeks of dosing in patients with stable schizophrenia on standard of care Oral, once-daily CY6463 was well tolerated, with no reports of serious adverse events (SAEs) or treatment discontin...

CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced the appointment of Steven E. Hyman, M.D., to its Board of Directors...

Data for CY6463, a first-in-class, CNS-penetrant, sGC stimulator, demonstrate safety and positive effects across biomarkers of disease in MELAS patients Company leadership discussed key insights for patients with MELAS with clinician-researcher, Amel Karaa, M.D., and Philip Yeske,...

Company to discuss positive topline and additional clinical data for CY6463 in MELAS patients Mitochondrial disease clinician-researcher, Amel Karaa, M.D., to discuss the potential future impact on patients Webcast scheduled for Tuesday, June 28 th from 8 &#x...

Cyclerion Therapeutics (NASDAQ:CYCN) is trading 12% higher after it said on Friday research from preclinical studies showed that treatment with its lead product, CY6463, was associated with improved cellular energetics and reduced inflammation in mitochondrial disease. Mitochon...

CY6463 alleviated mitochondrial dysfunction and reduced inflammation in preclinical models of mitochondrial complex 1 deficiency Data provide support for ongoing CY6463 clinical studies in CNS diseases associated with mitochondrial dysfunction CAMBRIDGE, Mass., June 17, 20...

Clinical-stage biotech Cyclerion Therapeutics (NASDAQ:CYCN)  announced mid-stage data for its lead candidate CY6463 on Friday from a trial involving adults with orphan disease Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS). Considered as the commonest t...

Data from an eight-patient, open-label study demonstrate improvements across multiple biomarkers of mitochondrial function, inflammation, cerebral blood flow, and functional connectivity CY6463 was well tolerated, with no reports of serious adverse events (SAEs) or treatment dis...